title: [Comparison of antiviral responses to adefovir dipivoxil therapy of genotype B and genotype C HBV infected patients].
abstract: OBJECTIVE
  To investigate the role of HBV genotypes on their response to adefovir dipivoxil (ADV) antiviral therapy.
  
  
  METHODS
  HBV genotypes from 177 HBeAg-positive chronic hepatitis B (CHB) patients were identified and the patients were treated with ADV 10 mg per day for 48 weeks. The clinical data in terms of serum HBV DNA seroclearance, mean HBV DNA reduction (log value), HBeAg loss, anti-HBe seroconversion and serum ALT of those patients were analyzed against their HBV genotypes.
  
  
  RESULTS
  Genotype B and genotype C were found in 102 and 65 cases, respectively. The mean HBV DNA reduction in patients with genotype B and genotype C at their treatment times of 12, 24 and 48 weeks was 2.2 log10copies/ml, 2.1 log10copies/ml (P more than 0.05), 2.7 log10copies/ml, 2.4 log10copies/ml (P more than 0.05) and 3.6 log10copies/ml, 3.1 log10copies/ml (P less than 0.05), respectively. At the end of the therapy (48 weeks), 43 (42.2%) patients with genotype B HBV infection and 22 (33.8%) patients with genotype C HBV infection had achieved HBV DNA seroclearance (P less than 0.05).
  
  
  CONCLUSIONS
  Our results suggest that genotype B HBV has a better virological response to ADV therapy in HBeAg-positive chronic hepatitis B patients than that of genotype C. Longer terms of ADV treatment are needed to confirm this conclusion.
authors.affiliation: Institute for Viral Hepatitis, Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University. Chongqing 400010, China.
authors.forename: Ai-zhong
authors.initials: AZ
authors.lastname: Zeng
authors.forename: Hui
authors.initials: H
authors.lastname: Deng
authors.forename: Feng-ying
authors.initials: FY
authors.lastname: Peng
authors.forename: Xiao-juan
authors.initials: XJ
authors.lastname: Xin
authors.forename: Chun
authors.initials: C
authors.lastname: Yang
authors.forename: Qing-ling
authors.initials: QL
authors.lastname: Li
authors.forename: Jin-jun
authors.initials: JJ
authors.lastname: Guo
authors.forename: Zhen-zhen
authors.initials: ZZ
authors.lastname: Zhang
authors.forename: Mei-jun
authors.initials: MJ
authors.lastname: Hao
authors.forename: Zhe
authors.initials: Z
authors.lastname: Yuan
authors.forename: Wen-xiang
authors.initials: WX
authors.lastname: Huang
authors.forename: Ai-long
authors.initials: AL
authors.lastname: Huang
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004279:DNA, Viral; D005260:Female; D005838:Genotype; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics*; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D063065:Organophosphonates; D000225:Adenine; C106812:adefovir dipivoxil